Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan and Inhaled Nitric Oxide in Septic Shock
NCT00800306Phase 2Completed
- Sponsor
- Sapienza University of Rome
- Start
- Nov 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of levosimendan in septic shock (2 arms), sponsored by Sapienza University of Rome. Primary endpoints: Systemic Hemodynamics at 36 hours and Microcirculatory Flow Index at 36 hours. Started Nov 2007; status: completed.
02
Drugs
levosimendan
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT00800306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800306.